PURPOSETo assess the safety and efficacy of the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor osimertinib as neoadjuvant therapy in patients with surgically ...

Background: Trastuzumab-pertuzumab combined with taxanes or eribulin has emerged as a promising therapeutic regimen for HER2-positive breast cancer, a subtype known for its aggressive clinical course.